PRLD Stock Price, Prelude Therapeutics orporated Quote, Chart

Market Summary

USD4.29+0.01

Delayedas of 17 May 2024, 09:39 am

0.23%

PRLD Stock Price

View Fullscreen

PRLD RSI Chart

PRLD Valuation

Market Cap

235.1M

Price/Earnings (Trailing)

-1.87

Price/Free Cashflow

-2.1

PRLD Price/Earnings (Trailing)

PRLD Profitability

Return on Equity

-59.58%

Return on Assets

-50.81%

Free Cashflow Yield

-47.52%

PRLD Fundamentals

PRLD Earnings

Earnings (TTM)

-125.5M

Earnings Growth (Yr)

-13.4%

Earnings Growth (Qtr)

4.97%

Breaking Down PRLD Revenue

52 Week Range

2.656.03

(Low)(High)

Last 7 days

2.7%

Last 30 days

-14.9%

Last 90 days

-9.7%

Trailing 12 Months

-33.7%

How does PRLD drawdown profile look like?

PRLD Financial Health

Current Ratio

11.64

PRLD Investor Care

Shares Dilution (1Y)

14.54%

Diluted EPS (TTM)

-1.87

Tracking the Latest Insider Buys and Sells of Prelude Therapeutics Incorporated

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 04, 2024	huang jane	sold (taxes)	-15,864	4.74	-3,347	president, cmo
Apr 04, 2024	huang jane	acquired	-	-	9,375	president, cmo
Jan 04, 2024	huang jane	sold (taxes)	-14,491	3.77	-3,844	president, cmo
Jan 04, 2024	huang jane	acquired	-	-	9,375	president, cmo
Oct 04, 2023	huang jane	acquired	-	-	9,375	president, cmo
Jul 04, 2023	huang jane	acquired	-	-	9,375	president, cmo
Jul 04, 2023	huang jane	sold (taxes)	-15,075	4.65	-3,242	president, cmo
May 25, 2023	vaddi krishna	bought	4,779	5.31	900	ceo
May 24, 2023	vaddi krishna	bought	5,011	5.0114	1,000	ceo
May 24, 2023	lim bryant david	bought	12,936	5.39	2,400	chief legal officer, corp sec.

Which funds bought or sold PRLD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	3.97	38,357	287,230	-%
May 15, 2024	ORBIMED ADVISORS LLC	unchanged	-	5,127,350	51,709,900	0.95%
May 15, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	unchanged	-	1,942,510	19,590,400	0.34%
May 15, 2024	Royal Bank of Canada	reduced	-77.29	-29,000	10,000	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-2.93	22,988	319,604	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-68.75	-265,832	141,228	-%
May 15, 2024	ZACKS INVESTMENT MANAGEMENT	new	-	87,484	87,484	-%
May 15, 2024	STATE STREET CORP	reduced	-0.37	95,991	1,002,230	-%
May 15, 2024	MORGAN STANLEY	reduced	-0.87	128,150	1,404,010	-%
May 15, 2024	KENNEDY CAPITAL MANAGEMENT LLC	new	-	118,666	118,666	-%

Are Funds Buying or Selling PRLD?

Are funds buying PRLD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PRLD

No. of Funds

Unveiling Prelude Therapeutics Incorporated's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	ubs asset management americas inc	0%	0	SC 13G/A
Feb 12, 2024	vaddi krishna	11.1%	4,908,086	SC 13G/A
Feb 12, 2024	flynn james e	9.85%	4,133,000	SC 13G/A
Jan 10, 2024	fmr llc	-	0	SC 13G/A
Dec 13, 2023	baker bros. advisors lp	24.3%	10,222,968	SC 13D/A
Nov 13, 2023	flynn james e	7.68%	3,222,690	SC 13G
May 24, 2023	baker bros. advisors lp	19.5%	10,219,080	SC 13D/A
May 24, 2023	orbimed advisors llc	28.6%	15,716,642	SC 13D/A
Feb 13, 2023	ubs asset management americas inc	5.24%	2,507,992	SC 13G
Feb 10, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of Prelude Therapeutics Incorporated

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 16, 2024	8-K/A	Current Report
May 08, 2024	EFFECT	EFFECT
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 06, 2024	S-3/A	S-3/A
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 10, 2024	8-K	Current Report

Peers (Alternatives to Prelude Therapeutics Incorporated)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Prelude Therapeutics Incorporated News

Latest updates

Prelude Therapeutics Incorporated Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-11.0%	247	278	259	281	198	221	242	259	281	305	331	350	370	224	240	167	94.00	22.00	16.00
Current Assets	-12.8%	205	236	235	260	175	204	227	249	270	295	326	345	365	221	238	-	-	20.00	16.00
Cash Equivalents	-2.3%	25.00	25.00	16.00	26.00	18.00	31.00	52.00	51.00	52.00	32.00	61.00	343	363	218	235	-	-	19.00	16.00
Net PPE	-0.4%	7.00	7.00	7.00	6.00	5.00	5.00	5.00	4.00	4.00	4.00	3.00	3.00	3.00	2.00	2.00	-	-	2.00	1.00
Liabilities	-10.4%	36.00	41.00	20.00	19.00	23.00	25.00	25.00	18.00	19.00	19.00	20.00	15.00	13.00	11.00	11.00	9.00	7.00	5.00	3.00
Current Liabilities	-19.2%	18.00	22.00	17.00	15.00	20.00	22.00	22.00	16.00	16.00	19.00	20.00	15.00	12.00	11.00	11.00	-	-	5.00	2.00
Shareholder's Equity	-11.1%	211	237	238	262	175	195	217	241	262	286	311	334	357	212	228	-	-	-	-
Retained Earnings	-6.9%	-487	-456	-423	-392	-362	-334	-305	-275	-248	-219	-186	-155	-128	-107	-88.18	-	-	-50.50	-22.93
Additional Paid-In Capital	0.8%	699	693	662	655	538	532	526	519	513	506	498	490	485	320	316	-	-	1.00	0.00
Shares Outstanding	25.5%	76.00	60.00	57.00	52.00	48.00	47.00	47.00	47.00	47.00	46.00	46.00	46.00	-	-	-	-	-	-	-
Float	-	-	-	-	77.00	-	-	-	65.00	-	-	-	343	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	-34.8%	-31,791	-23,578	-25,683	-27,668	-30,134	-22,927	-20,439	-18,468	-21,895	-25,702	-21,774	-19,912	-16,143	-14,847	-12,507	-8,902	-9,921	-	-	-
Share Based Compensation	-6.2%	5,547	5,912	6,715	6,733	6,256	5,845	6,442	6,028	6,829	4,468	7,033	4,237	6,500	3,122	1,472	627	362	-	297	-
Cashflow From Investing	303.6%	31,221	7,736	15,045	-75,426	17,999	1,355	21,607	58,576	153	-1,804	-260,632	-381	-986	-329	-170	-42.00	-80.00	-	-	-
Cashflow From Financing	-100.1%	-14.00	25,237	88.00	111,339	-269	155	148	-41,036	41,548	1,954	711	422	161,810	-1,307	217,753	-65.00	29,847	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PRLD Income Statement

2024-03-31

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 27,409	$ 21,834
General and administrative	6,934	7,281
Total operating expenses	34,343	29,115
Loss from operations	(34,343)	(29,115)
Other income, net	2,912	1,397
Net loss	$ (31,431)	$ (27,718)
Per share information:
Net loss per share of common stock, basic	$ (0.42)	$ (0.58)
Net loss per share of common stock, diluted	$ (0.42)	$ (0.58)
Weighted average common shares outstanding, basic	75,735,954	47,737,190
Weighted average common shares outstanding, diluted	75,735,954	47,737,190
Comprehensive loss
Net loss	$ (31,431)	$ (27,718)
Unrealized (loss) gain on marketable securities, net of tax	(458)	1,294
Comprehensive loss	$ (31,889)	$ (26,424)

PRLD Balance Sheet

2024-03-31

BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 24,707	$ 25,291
Marketable securities	177,217	207,644
Prepaid expenses and other current assets	3,442	2,654
Total current assets	205,366	235,589
Restricted cash	4,044	4,044
Property and equipment, net	7,294	7,325
Right-of-use asset	30,107	30,412
Other assets	295	295
Total assets	247,106	277,665
Current liabilities:
Accounts payable	5,308	4,580
Accrued expenses and other current liabilities	10,147	15,768
Operating lease liability	2,188	1,481
Total current liabilities	17,643	21,829
Other liabilities	3,277	3,339
Operating lease liability	15,452	15,407
Total liabilities	36,372	40,575
Commitments (Note 8)
Stockholders’ equity:
Additional paid-in capital	698,785	693,252
Accumulated other comprehensive (loss) income	(235)	223
Accumulated deficit	(487,821)	(456,390)
Total stockholders’ equity	210,734	237,090
Total liabilities and stockholders’ equity	247,106	277,665
Voting Common Stock
Stockholders’ equity:
Common stock	4	4
Non-voting Common Stock
Stockholders’ equity:
Common stock	$ 1	$ 1

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma. The company is also developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 2 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

CEO	Dr. Krishna Vaddi D.V.M., Ph.D.
WEBSITE	https://preludetx.com
INDUSTRY	Biotechnology
EMPLOYEES	122

Prelude Therapeutics Incorporated Frequently Asked Questions

What is the ticker symbol for Prelude Therapeutics Incorporated? What does PRLD stand for in stocks?

PRLD is the stock ticker symbol of Prelude Therapeutics Incorporated. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Prelude Therapeutics Incorporated (PRLD)?

As of Thu May 16 2024, market cap of Prelude Therapeutics Incorporated is 235.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRLD stock?

You can check PRLD's fair value in chart for subscribers.

What is the fair value of PRLD stock?

You can check PRLD's fair value in chart for subscribers. The fair value of Prelude Therapeutics Incorporated is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Prelude Therapeutics Incorporated is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PRLD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Prelude Therapeutics Incorporated a good stock to buy?

The fair value guage provides a quick view whether PRLD is over valued or under valued. Whether Prelude Therapeutics Incorporated is cheap or expensive depends on the assumptions which impact Prelude Therapeutics Incorporated's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRLD.